RxDoctor Payments DataLook up a doctor →

Meghan Businaro, DO

Cardiovascular Disease · Columbia, SCNPI 1639326283

Payments from drug & device makers

$11,352in general payments, 2019–2025

Across 553 payments — averaging $20.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Novartis$2K
  • Philips North America LLC$987
  • Amgen$812
  • Pfizer$743
  • Alnylam Pharmaceuticals Inc.$612
  • plus $5K from 22 others

What the payments were for

  • Food & beverage$11,342100%
  • Education$100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,352 in reported general payments places this provider in the 75th percentile of 257 cardiovascular disease providers in South Carolina.

See all cardiovascular disease providers in South Carolina

Medicare billing

Part B allowed, 2024
$340,950
Medicare patients
1,794
Services billed
5,606

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban200$229,940
Repatha SureclickEvolocumab82$70,099
EntrestoSacubitril/Valsartan41$63,445
XareltoRivaroxaban30$38,269
JardianceEmpagliflozin20$26,436
NexlizetBempedoic Acid/Ezetimibe28$20,030
Repatha PushtronexEvolocumab16$16,214
FarxigaDapagliflozin Propanediol19$13,994
Praluent PenAlirocumab19$13,682
Metoprolol Succinate336$5,431
Losartan Potassium173$2,610
Olmesartan Medoxomil42$2,498
Ezetimibe67$2,496
Atorvastatin Calcium150$2,245
Diltiazem 24hr Er (Cd)Diltiazem Hcl44$1,962

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$743$229,940200 claims
NovartisEntresto$1,605$63,44541 claims
Johnson & JohnsonXarelto$171$38,26930 claims
Boehringer IngelheimJardiance$239$26,43620 claims
Esperion Therapeutics, Inc.Nexlizet$444$20,03028 claims
AstraZenecaFarxiga$527$13,99419 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 257 cardiovascular disease providers in South Carolina.

Other cardiovascular disease in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →